Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Zeng Jun, Li"'
Publikováno v:
HemaSphere, Vol 7, p e90361c0 (2023)
Externí odkaz:
https://doaj.org/article/226d9a2fd99a41edaeb96801e769955d
Publikováno v:
Precision Radiation Oncology, Vol 4, Iss 2, Pp 44-48 (2020)
Abstract Objectives At present, locating radiotherapy targets for rectal cancer is mostly assisted by computed tomography (CT) and/or magnetic resonance (MR) imaging. This article discusses the role of the upper and lower margins of rectal cancer les
Externí odkaz:
https://doaj.org/article/533e11f28eef466a9af661f2fadf9b6f
Autor:
Heng Li, Shu-Hua Yi, Wen-Jie Xiong, Hui-Min Liu, Rui Lyu, Ting-Yu Wang, Wei Liu, Shi-Zhen Zhong, Zhen Yu, De-Hui Zou, Yan Xu, Gang An, Zeng-Jun Li, Lu-Gui Qiu
Publikováno v:
Chinese Medical Journal, Vol 130, Iss 2, Pp 135-142 (2017)
Background: The established clinical staging systems (Rai/Binet) of chronic lymphocytic leukemia (CLL) cannot accurately predict the appropriate treatment of patients in the earlier stages. In the past two decades, several prognostic factors have bee
Externí odkaz:
https://doaj.org/article/d75a942e0cbf44f5a802bb0c78bacd1c
Publikováno v:
OncoTargets and therapy
Familial adenomatous polyposis (FAP) is a rare autosomal dominant genetic disease related to germline mutations of the APC gene. The clinical features of this disease most commonly include hundreds of adenomas or polyps. If not treated in a timely fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a34244d3c252b17243c96de89bd996e6
https://doi.org/10.2147/ott.s183153
https://doi.org/10.2147/ott.s183153
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e71516 (2013)
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) plays an important role in cancer development. The relationship between PIN1 -842G/C (rs2233678) polymorphism and cancer risk was inconclusive according to published literature.A literatur
Externí odkaz:
https://doaj.org/article/2a30c794cf914bdcb58f79102550a511
Publikováno v:
SSRN Electronic Journal.
Colon cancer (CC) currently ranks as the third most common human cancer worldwide with an increasing incidence and a poor prognosis. Recently, circular RNAs (circRNAs) have been reported to regulate the progression of diverse human cancers. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::598f0fb9964b89ba3804f67a550993fa
https://doi.org/10.2139/ssrn.3685935
https://doi.org/10.2139/ssrn.3685935
Autor:
Xin, Li, Wan-jun, Sun, Zeng-jun, Li, Yao-zhong, Zhao, Yun-tao, Li, Yan, Li, Chang-chun, Wan, Qiao-chuan, Li, Ren-chi, Yang, Ming-zhe, Han, Jian-xiang, Wang, Lu-gui, Qiu
Publikováno v:
In Leukemia Research 2007 31(6):765-771
Autor:
Rui, Lu, Zeng-Jun, Li, Gang, An, Shu-Hua, Yi, Wei, Liu, Ting-Yu, Wang, Shu-Hui, Deng, Wei-Wei, Sui, De-Hui, Zou, Lu-Gui, Qiu
Publikováno v:
Zhongguo shi yan xue ye xue za zhi. 27(3)
To investigate the clinical characteristics and therapeutic responte of patients with B-CLPD mainly manifested as cytopenia, so as to deeply understand this disease.The clinical data of 13 B-CLPD patients with hematocytopenia as main manifestation, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bceb78f39b6730a55661409cb7bf1e1d
https://pubmed.ncbi.nlm.nih.gov/31204941
https://pubmed.ncbi.nlm.nih.gov/31204941
Publikováno v:
Oncology Reports. 35:1403-1408
The emerging role of microRNA-181A (miR-181A) in CRC patients with late liver metastases was studied. In the present study we investigated the association between expression and mechanism of miRNA-181A, liver metastasis and prognosis of colorectal ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4477b26e0523d1dc39875ea7ef8abf1
https://doi.org/10.3892/or.2016.4546
https://doi.org/10.3892/or.2016.4546
Autor:
Heng, Li, Wen Jie, Xiong, Hui Min, Liu, Shu Hua, Yi, Rui, Lü, Ting Yu, Wang, Zhen, Yu, Lu Gui, Qiu, Zeng Jun, Li
Publikováno v:
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. 39(6)
Objective To evaluate the efficacy of rituximab in treating chronic lymphocytic leukemia (CLL). Methods The clinical data of CLL patients receiving fludarabine,cyclophosphamide±rituximab (with or without rituximab) regimen or cyclophosphamide,vincri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85e730ca872ca07154ddfb9a23d7fb77
https://pubmed.ncbi.nlm.nih.gov/29338825
https://pubmed.ncbi.nlm.nih.gov/29338825